Murphy SA, et al. - In this investigation involving 27,564 patients (mean 63 years), researchers assessed the impact of evolocumab on total cardiovascular events, given the importance of a total number of cardiovascular events to patients, clinicians, and health economists. Investigators found that adding the PCSK9 inhibitor evolocumab to statin therapy enhanced clinical outcomes, with significant decreases in total primary end point events, driven by reductions in myocardial infarction, stroke, and coronary revascularization. They observed that there were 2192 total primary events in the evolocumab group and 2714 total events in the placebo group. Evolocumab vs placebo prevented more than double the number of events compared to analyzing only the first events. This information provides further assistance in order to avoid recurrent cardiovascular events by continuing aggressive lipid-lowering treatment.